Before you sell to, join or invest in Kamau Therapeutics, Inc.
MentionFox check on Kamau Therapeutics, Inc.: only 1 source on file so far (checked 4 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/kamau-therapeutics-inc-form-d-25000001
Check Kamau Therapeutics, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about Kamau Therapeutics, Inc.?
Based on the record MentionFox holds for this company. No flag is not a clearance.
Kamau Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-06-03.
Kamau Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on June 3, 2025. The filing reports $5M sold. Its industry group is Other Technology. It names Valentin Barsan (Executive Officer, Director), Matthew Porteus (Executive Officer, Director), Ness Bermingham (Director) (SEC Form D, June 3, 2025).
Is this your company?
Sell to companies like Kamau Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-06-03 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Kamau Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Kamau Therapeutics, Inc., from the filings we hold.
Other Technology raises by companies based in California, filed in June 2025, largest first.
Get an email when Kamau Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Kamau Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Kamau Therapeutics, Inc. →Get the full cited report on Kamau Therapeutics, Inc.
What the filing shows about Kamau Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Kamau Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Kamau Therapeutics, Inc.'s address as 220 E. Grand Avenue, South San Francisco, CA 94080.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Kamau Therapeutics, Inc. See pricing
Kamau Therapeutics, Inc. is a registered filer with the SEC (CIK 2071165) and has filed since 2025-06-03. 1 filing is on record, the latest on 2025-06-03.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Kamau Therapeutics, Inc.'s Form D of 2025-06-03 names Valentin Barsan, Matthew Porteus, Ness Bermingham and 1 more as its officers, directors or promoters.
Its new offerings report $5M sold across 1 offering, as its own filings state.
Trailing twelve months. 3839 filings in Other Technology, totalled by week.
Valentin Barsan is named as Executive Officer and Director on the Form D that Kamau Therapeutics, Inc. filed with the SEC on 3 June 2025, one of 4 people that filing names.
Matthew Porteus is named as Executive Officer and Director on the Form D that Kamau Therapeutics, Inc. filed with the SEC on 3 June 2025, one of 4 people that filing names.
Ness Bermingham is named as Director on the Form D that Kamau Therapeutics, Inc. filed with the SEC on 3 June 2025, one of 4 people that filing names.
Raymond Kelleher is named as Director on the Form D that Kamau Therapeutics, Inc. filed with the SEC on 3 June 2025, one of 4 people that filing names.
4 people named on the filing — 2 holding an executive role and 2 as directors only.
Named as of the 2025-06-03 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Kamau Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Kamau Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kamau Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Kamau Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Kamau Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Kamau Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: AI and software raises in San Francisco Bay Area
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/kamau-therapeutics-inc-form-d-25000001